Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors

A compound of Formula (I):

• or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, wherein:
• ring A is independently phenyl substituted with 0-1 R6 and 0-2 R7;
• R1 is independently selected from:
• —(CH2)m—(C3-6 carbocycle substituted with 0-2 Rb and 0-2 Rg), —(CH2)m-(5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O and S;
• wherein said heteroaryl is substituted with 0-1 Rb and 0-2 Rg), and (a C1-12 hydrocarbon chain substituted with 0-3 Ra;
• wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated);
• R2 is independently selected from:
• C1-4 alkyl, C3-4 cycloalkyl, and C1-4 haloalkyl;
• R3 is independently selected from:
• H, F, C1-4 alkyl and CN;
• R4 is independently selected from:
• H, F, and C1-4 alkyl;
• R3 and R4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;
• R6 is independently selected from:
• halogen, C1-6 alkyl substituted with 0-2 Rh, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CO(C1-4 alkyl), —(CH2)m—C3-6 carbocycle, —(CH2)m—NRfRi, CN, ORi, SRi, and (a 4- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O, and S);
• R7 is independently selected from:
• halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
• alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising carbon atoms and 1-3 heteroatoms selected from N, NRe, O, and S;
• wherein said heterocycle is substituted with 0-2 Rg;
• Ra is, at each occurrence, independently selected from:
• halogen, OH, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, N(C1-4 alkyl)2, COOH, and —(CH2)n—R;
• Rb is, at each occurrence, independently selected from:
• halogen, OH, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 haloalkoxy, C1-10 alkylthio, C1-10 haloalkylthio, N(C1-4 alkyl)2, —CONH(C4-20 alkyl), —CONH(C4-20 haloalkyl), —O(CH2)sO(C1-6 alkyl), —O(CH2)sO(C1-6 haloalkyl), Rc, and —(CH2)n—(O)t—(CH2)mRc;
• Rc is, at each occurrence, independently selected from:
• C3-6 cycloalkyl substituted with 0-2 Rd, C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)m-(phenyl substituted with 0-3 Rd), and (a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O, and S;
• wherein said heterocycle is substituted with 0-2 Rd);
• Rd is, at each occurrence, independently selected from:
• halogen, OH, CN, NO2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, tetrazolyl, OBn and phenyl;
• Re is, at each occurrence, independently selected from:
• H, C1-8 alkyl, C1-8 haloalkyl, —(CH2)n—C3-6 carbocycle, CO(C1-4 alkyl) and COBn;
• Rf is, at each occurrence, independently selected from:
• H and C1-4 alkyl;
• Rg is, at each occurrence, independently selected from:
• halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
• Rh is, at each occurrence, independently selected from:
• OH, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
• Ri is, at each occurrence, independently selected from the group consisting of C1-4 alkyl, C3-4 cycloalkyl and phenyl;
• n, at each occurrence, is independently 0 or 1;
• m, at each occurrence, is independently 0, 1, 2, 3, or 4;
• s, at each occurrence, is independently 1, 2, or 3;
• and
• t, at each occurrence, is independently 0 or 1.